Vertex (VRTX) Announces Health Canada Acceptance of NDS for Suzetrigine

Vertex Pharmaceuticals (NASDAQ:VRTX) is one of the 12 Most Profitable Stocks to Invest In.

On May 21, 2026, Vertex Pharmaceuticals (NASDAQ:VRTX) announced that Health Canada accepted for review a New Drug Submission for suzetrigine for the treatment of moderate-to-severe acute pain in adults. Vertex said suzetrigine is a selective NaV1.8 pain signal inhibitor and represents a new class of oral pain medicine that is not an opioid or a nonsteroidal anti-inflammatory drug. If approved, suzetrigine could become the first new class of medicine in Canada to treat acute pain in more than twenty years.

On May 5, 2026, RBC Capital analyst Brian Abrahams raised the firm’s price target on Vertex Pharmaceuticals (NASDAQ:VRTX) to $543 from $541 and maintained an Outperform rating on the shares. Abrahams said the stock had been weak recently due to perceptions of higher risk around the near-term catalyst path, but that decent Q1 results, operational confidence for the rest of 2026, and reaffirmation of “pove’s clean safety” were a good start toward clearing overhangs.Vertex (VRTX) Announces Health Canada Acceptance of NDS for Suzetrigine

Earlier in May, Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q1 EPS of $4.02, versus the consensus estimate of $4.31. Revenue totaled $2.99B, compared to the consensus estimate of $3.00B. CEO and President Reshma Kewalramani said Vertex was off to a “strong start” in 2026, driven by cystic fibrosis leadership, growth in sickle cell disease, beta thalassemia, and acute pain, and rapid pipeline progress. Kewalramani added that CASGEVY and JOURNAVX delivered more than 25% of the company’s growth during the quarter.

Vertex Pharmaceuticals (NASDAQ:VRTX) operates as a biotechnology company in the United States, Europe, and internationally.

While we acknowledge the risk and potential of VRTX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than VRTX and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1